Polaryx Pushes PLX‑200 Through SOTERIA Phase 2, Strengthening Commitment to Rare Pediatric LSDs on Rare Disease Day
Polaryx Therapeutics reaffirms its focus on rare pediatric lysosomal storage disorders, highlighting PLX‑200’s Phase 2 SOTERIA trial progress and a commitment to disease‑modifying treatments.
3 minutes to read